Abstract
Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints.
Cite
CITATION STYLE
APA
Korn, E. L., & Freidlin, B. (2018). Surrogate and intermediate endpoints in randomized trials: What’s the goal? Clinical Cancer Research, 24(10), 2239–2240. https://doi.org/10.1158/1078-0432.CCR-18-0183
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free